LIVE WEBINAR: Thursday, February 8, 2024 | 5:00 PM – 6:00 PM Eastern Time (ET)

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Gastroesophageal Cancers

Join us on Thursday, February 8th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Yelena Y Janjigian, MD
Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, and Merck.

Thursday, February 8, 2024
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • PART I: Immunotherapy for Gastroesophageal Cancers
  • PART II: Other Treatment Approaches for Gastroesophageal Cancers

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other allied healthcare professionals involved in the treatment of gastroesophageal cancers.

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Use HER2 status, PD-L1 combined positive score, microsatellite instability/mismatch repair deficiency status, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
  • Optimally incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer in patients who have experienced disease progression on front-line therapy.
  • Appraise clinical trial findings supporting the use of neoadjuvant and/or adjuvant anti-PD-1/PD-L1 antibody therapy in patients with resectable gastric, GEJ and esophageal cancers, and discern the clinical applicability of various treatment strategies.
  • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer, and optimally identify candidates who may be appropriate for these approaches.
  • Evaluate the biological rationale for the investigation of claudin 18.2 as a therapeutic target in gastric/GEJ cancer, and assess available data with novel strategies directed at this emerging biomarker.
  • Review the rationale for, available data with and ongoing research studies evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr JanjigianAdvisory Committees and Consulting Agreements: AbbVie Inc, Amerisource Bergen, Arcus Biosciences, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Geneos Therapeutics, GSK, Guardant Health, Imugene, Inspirna, Lilly, Lynx Health LLC, Merck, Merck Serono, Mersana Therapeutics Inc, Pfizer Inc, Seagen Inc, Silverback Therapeutics, Zymeworks Inc; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Inspirna, Lilly, Merck, Transcenta; Data and Safety Monitoring Boards/Committees: Arcus Biosciences, Daiichi Sankyo Inc, Transcenta; Stock Options — Private Company: Inspirna; Nonrelevant Financial Relationships: Clinical Care Options, Cycle for Survival, Fred's Team, HMP Education, Imedex, MJH Life Sciences, National Cancer Institute, Paradigm Medical Communications, PeerView Institute, US Department of Defense. Dr WainbergConsulting Agreements: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Seagen Inc; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Compass Therapeutics, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, and Merck.